# Treatment for Advanced B-Cell Lymphoma

> **NCT01859819** · PHASE2 · COMPLETED · sponsor: **New York Medical College** · enrollment: 45 (actual)

## Conditions studied

- Diffuse Large Cell Lymphoma
- Burkitt's Lymphoma
- High Grade B-cell Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** IT Cytarabine

## Key facts

- **NCT ID:** NCT01859819
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2020-06
- **Final completion:** 2021-06
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2022-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01859819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01859819, "Treatment for Advanced B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01859819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*